Stock Market News
ValiRx soars on anti-cancer compound's successful study
Clinical stage biotechnology company ValiRx has seen positive results from recent studies into the effectiveness of its VAL101 compound's ability to induce cancer cells to kill themselves off.
ValiRx's studies, which involved a wide range of technical and scientific methodologies demonstrating the enhanced effect of VAL101 on the prevention of cancer growth at cellular biochemical and genomic levels, showed a superior apoptotic effect in comparison to currently available reagents. Apoptosis is the death of cells which occurs as a normal and controlled part of an organism's growth or development.
The AIM-quoted firm has decided to progress its VAL101 programme towards the clinic in a full partnership with its existing commercial and academic collaborators in Finland, Germany and Denmark, as it also sought to add new commercial partners in the US and China in order to support the compound's manufacturing and clinical development.
Dr Satu Vainikka, chief executive officer of ValiRx, said, "Our previous two Eurostars Awards have clearly demonstrated and endorsed the importance of the project, which is targeting a very important and increasingly prominent area of the therapeutic industry, namely targeted and personalised therapies."
"I am also delighted by the technical excellence and high quality of the work conducted by the Consortium, which is extremely innovative. I look forward to the future development of this exciting field and to the development of VAL101 and further related GeneICE compounds. I also expect the results of these studies to be written up and submitted for publication in a relevant peer-reviewed journal," he added.
As of 0840 BST, shares had soared 40% to 3.85p.
ValiRx's studies, which involved a wide range of technical and scientific methodologies demonstrating the enhanced effect of VAL101 on the prevention of cancer growth at cellular biochemical and genomic levels, showed a superior apoptotic effect in comparison to currently available reagents. Apoptosis is the death of cells which occurs as a normal and controlled part of an organism's growth or development.
The AIM-quoted firm has decided to progress its VAL101 programme towards the clinic in a full partnership with its existing commercial and academic collaborators in Finland, Germany and Denmark, as it also sought to add new commercial partners in the US and China in order to support the compound's manufacturing and clinical development.
Dr Satu Vainikka, chief executive officer of ValiRx, said, "Our previous two Eurostars Awards have clearly demonstrated and endorsed the importance of the project, which is targeting a very important and increasingly prominent area of the therapeutic industry, namely targeted and personalised therapies."
"I am also delighted by the technical excellence and high quality of the work conducted by the Consortium, which is extremely innovative. I look forward to the future development of this exciting field and to the development of VAL101 and further related GeneICE compounds. I also expect the results of these studies to be written up and submitted for publication in a relevant peer-reviewed journal," he added.
As of 0840 BST, shares had soared 40% to 3.85p.
Related share prices |
---|
Valirx (VAL) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price